Astrazeneca (AZN) Gross Profit (2009 - 2026)

Astrazeneca (AZN) has reported Gross Profit for 18 consecutive years, with $12.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 11.13% year-over-year to $12.6 billion; the TTM figure through Mar 2026 stood at $49.4 billion (up 10.32% YoY), while the FY2025 annual figure was $48.1 billion, up 9.67% from the prior year.
• Gross Profit came in at $12.6 billion for Q1 2026 at Astrazeneca, up from $12.4 billion in the prior quarter.
• The five-year high for Gross Profit was $12.6 billion in Q1 2026, with the low at $7.8 billion in Q2 2022.
• Average Gross Profit over 5 years is $10.2 billion, with a median of $10.5 billion recorded in 2024.
• Across the five-year window, Gross Profit jumped 82.77% in 2022 and gained 1.8% in 2025, its largest moves.
• Year by year, Gross Profit stood at $8.3 billion in 2022, then gained by 16.96% to $9.7 billion in 2023, then advanced by 25.22% to $12.2 billion in 2024, then climbed by 1.8% to $12.4 billion in 2025, then rose by 1.82% to $12.6 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $12.6 billion, $12.4 billion, and $12.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.